Crescita Therapeutics Inc. (CTX.TO)
CAD 0.57
(0.0%)
CAD 0.57
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 815 Thousand CAD | -32.53% |
| 2022 | 1.2 Million CAD | -20.79% |
| 2021 | 1.52 Million CAD | 63.45% |
| 2020 | 933 Thousand CAD | -21.6% |
| 2019 | 1.19 Million CAD | -58.29% |
| 2018 | 2.85 Million CAD | -10.14% |
| 2017 | 3.17 Million CAD | -57.33% |
| 2016 | 7.44 Million CAD | 0.0% |
| 2015 | - CAD | 0.0% |
| 2014 | - CAD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 588 Thousand CAD | 0.0% |
| 2024 Q1 | 702 Thousand CAD | 0.0% |
| 2023 FY | 815 Thousand CAD | -32.53% |
| 2023 Q1 | 1.1 Million CAD | -8.61% |
| 2023 Q2 | 999 Thousand CAD | -9.51% |
| 2023 Q3 | 892 Thousand CAD | -10.71% |
| 2023 Q4 | 815 Thousand CAD | -8.63% |
| 2022 Q3 | 1.23 Million CAD | -7.19% |
| 2022 Q1 | 1.43 Million CAD | -6.23% |
| 2022 FY | 1.2 Million CAD | -20.79% |
| 2022 Q2 | 1.33 Million CAD | -6.64% |
| 2022 Q4 | 1.2 Million CAD | -2.5% |
| 2021 Q1 | 2.74 Million CAD | 194.21% |
| 2021 Q4 | 1.52 Million CAD | -5.75% |
| 2021 Q3 | 1.61 Million CAD | -5.38% |
| 2021 Q2 | 1.71 Million CAD | -37.7% |
| 2021 FY | 1.52 Million CAD | 63.45% |
| 2020 Q2 | 1.01 Million CAD | -8.06% |
| 2020 Q1 | 1.1 Million CAD | -7.23% |
| 2020 Q4 | 933 Thousand CAD | 1.08% |
| 2020 Q3 | 923 Thousand CAD | -9.06% |
| 2020 FY | 933 Thousand CAD | -21.6% |
| 2019 Q4 | 1.19 Million CAD | -75.37% |
| 2019 Q2 | 4.9 Million CAD | -1.47% |
| 2019 FY | 1.19 Million CAD | -58.29% |
| 2019 Q1 | 4.98 Million CAD | 74.55% |
| 2019 Q3 | 4.83 Million CAD | -1.53% |
| 2018 Q1 | 3.19 Million CAD | 0.72% |
| 2018 FY | 2.85 Million CAD | -10.14% |
| 2018 Q4 | 2.85 Million CAD | -7.31% |
| 2018 Q3 | 3.07 Million CAD | -4.44% |
| 2018 Q2 | 3.22 Million CAD | 0.72% |
| 2017 Q3 | 4.26 Million CAD | -37.67% |
| 2017 Q2 | 6.84 Million CAD | -4.21% |
| 2017 FY | 3.17 Million CAD | -57.33% |
| 2017 Q1 | 7.14 Million CAD | -3.99% |
| 2017 Q4 | 3.17 Million CAD | -25.56% |
| 2016 Q1 | - CAD | 0.0% |
| 2016 Q4 | 7.44 Million CAD | -5.6% |
| 2016 Q3 | 7.88 Million CAD | 0.0% |
| 2016 Q2 | - CAD | 0.0% |
| 2016 FY | 7.44 Million CAD | 0.0% |
| 2015 FY | - CAD | 0.0% |
| 2015 Q1 | - CAD | 0.0% |
| 2015 Q4 | - CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Aurora Cannabis Inc. | 47.57 Million CAD | 98.287% |
| Avicanna Inc. | 95.36 Thousand CAD | -754.638% |
| Avant Brands Inc. | 1.74 Million CAD | 53.188% |
| Cardiol Therapeutics Inc. | 158.53 Thousand CAD | -414.092% |
| Knight Therapeutics Inc. | 44.01 Million CAD | 98.148% |
| MediPharm Labs Corp. | 69 Thousand CAD | -1081.159% |
| OrganiGram Holdings Inc. | 79 Thousand CAD | -931.646% |
| Canopy Growth Corporation | 493.29 Million CAD | 99.835% |
| Willow Biosciences Inc. | 594 Thousand CAD | -37.205% |
| Auxly Cannabis Group Inc. | 81.38 Million CAD | 98.999% |